Timothée Olivier, MD (@Timothee_MD)

Pinned

T

Timothée Olivier, MD@Timothee_MD · May 29

x.com/i/article/1928…

4

24

64

37

11.0K

Pinned

T

Timothée Olivier, MD@Timothee_MD · Jul 22

To be fair, Laura isn’t equipped to evaluate @VPrasadMDMPH's role; it’s beyond her skillset. Vinay is a scientist at the FDA. Yes, he has personal values that change and don’t neatly align with any one party or politician. But science isn’t about opinion; it’s about data. Unlike…

LLaura Loomer@LauraLoomer · Jul 21

NEW: Meet Vinay Prasad: The Progressive Leftist Saboteur Undermining President Trump’s FDA The vetting crisis continues… @VPrasadMDMPH @US_FDA @RobertKennedyJr @SergioGor loomered.com/2025/07/20/mee…

9

4

24

0

3.0K

T

Timothée Olivier, MD@Timothee_MD · 5 h

Academic read of the day! Crossover in oncology? A concise, open-access, 2-page paper clearly framing when it is is desirable, and when its problematic, by @AlysonHaslam & @VPrasadMDMPH in @Annals_Oncology Seminal 2018 paper and still as relevant! ➡️bit.ly/3TZCOUc

Timothee_MD's tweet image. Academic read of the day!

Crossover in oncology?

A concise, open-access, 2-page paper clearly framing when it is is desirable, and when its problematic, by @AlysonHaslam &amp; @VPrasadMDMPH in @Annals_Oncology

Seminal 2018 paper and still as relevant!
➡️bit.ly/3TZCOUc

1

3

33

14

1.0K

T

Timothée Olivier, MD@Timothee_MD · Jul 22

George Tidmarsh, MD, PhD, the new @FDACDERDirector, recently explained why he thinks that: "Dr. Peter Marks Was a Hero to Biotech Investors, Not Patients and Public Health" Grateful that @VPrasadMDMPH is now leading @FDACBER, succeeding Dr. Peter Marks A must read if you want…

2

11

5

2.0K

T

Timothée Olivier, MD@Timothee_MD · Jul 14

x.com/i/article/1944…

4

43

147

87

27.0K

Timothée Olivier, MD Retweeted

Y

Yair Einhorn@yaireinhorn · Jul 19

The major event which took place this week in the BioTech and Pharma sector was without a doubt the death of a third patient from @Sarepta’s Gene Therapy. Here’s an excellent short summary by @CNBC’s @angelicapeebles which explains what went wrong with $SRPT. Worth watching! $XBI

17

15

80

40

18.0K

T

Timothée Olivier, MD@Timothee_MD · Jul 19

Sarepta Doesn't Think The FDA, Insurance Cos & Gov't Sponsored Programs Paying $3.2MM For a 1 Time Not a Cure Dose with Little to No Benefit Should Have a Say If Patients Should Receive ELEVIDYS @POTUS @realDonaldTrump @PressSec @StephenM @RobertKennedyJr @MartyMakary $SRPT $UNH

..@brianfires · Jul 19

Organizations Paying for Patients to Receive the $3.2MM One Time Dose, ELEVIDYS, Should Have a Say Including Insurance Companies, Gov't Sponsored Programs & The FDA. ELEVIDYS Is Not a Cure. Benefits From ELEVIDYS Are Minimal & Risks Are High. Shouldn't Have Been Approved! $SRPT

0

1

2

0

868

T

Timothée Olivier, MD@Timothee_MD · Jul 19

A thoughtful and responsible decision by @DrMakaryFDA @VPrasadMDMPH @US_FDA after a third death potentially linked to Sarepta's products. “Protecting patient safety is our highest priority, and the FDA will not allow products whose harms are greater than benefits. The FDA will…

Timothee_MD's tweet image. A thoughtful and responsible decision by @DrMakaryFDA @VPrasadMDMPH @US_FDA after a third death potentially linked to Sarepta's products.

“Protecting patient safety is our highest priority, and the FDA will not allow products whose harms are greater than benefits. The FDA will…

3

5

20

3

3.0K

T

Timothée Olivier, MD@Timothee_MD · Jul 18

Head into the weekend with this 5-minute read on the myths and misunderstandings around surrogate endpoints in early breast cancer. I don’t bluff; this one’s worth your time. #BCSM #Oncology #EvidenceMatters

SSaroj Niraula@sarojniraula · Jul 2

Just published: Is iDFS a strong surrogate for OS in #bcsm? My @JCO_ASCO LTE challenges the claim: R² = 0.46 means 54% of OS variance remains unexplained, yet iDFS continues to drive decisions! Oncology needs stronger evidence standards Here: ascopubs.org/doi/10.1200/JC…

1

2

1

526

Timothée Olivier, MD Retweeted

A

Anil Makam@AnilMakam · Jul 18

this is how media narrative works CBER Director overrules on COVID vaccine to ensure more in line with evidence -gets skewered CBER Director overrules to approve a drug based on no evidence of benefit & worry harm signal -hardly a blip (until now with 3 deaths)

0

2

17

1

2.0K

T

Timothée Olivier, MD@Timothee_MD · Jul 18

yes & no it isn't about you or about the investigators check everyone's ego at the door intent is irrelevant IMO It's entirely about patient care & societal good if poorly designed or very biased, little to nothing is learned often no data is better than bad/biased data

VVincent Rajkumar@VincentRK · Jul 18

So you have learnt how to critically appraise the literature… How you use those skills is important. The goal should not be to display one’s critical appraisal skills. This is not a contest. We can find flaws in every trial. If you did a trial, chances are when it’s published…

0

1

9

0

1.0K

T

Timothée Olivier, MD@Timothee_MD · Jul 17

Hot off the press a 🚨 Must-read review on optimizing treatment for #LungCancer with activating EGFR mutations , a true game changer in targeted therapy. TKIs have transformed outcomes, but the journey continues. 👉 acsjournals.onlinelibrary.wiley.com/doi/full/10.33… thanks to all the co-authors, great team…

CCA: A Cancer Journal for Clinicians@CACancerJournal · Jul 17

Activating mutations in EGFR gene has revolutionized management of #LungCancer, enabling development of TKIs. New review on strategies to optimize treatment: acsjournals.onlinelibrary.wiley.com/doi/full/10.33… @Alfdoc2 @Maxime_Borgeaud @Timothee_MD @JairBar4 @kaushalpar @jillfeldman4 @LeXiuning @OncoAlert

6

26

69

21

10.0K

Timothée Olivier, MD Retweeted

C

CA: A Cancer Journal for Clinicians@CACancerJournal · Jul 17

Activating mutations in EGFR gene has revolutionized management of #LungCancer, enabling development of TKIs. New review on strategies to optimize treatment: acsjournals.onlinelibrary.wiley.com/doi/full/10.33… @Alfdoc2 @Maxime_Borgeaud @Timothee_MD @JairBar4 @kaushalpar @jillfeldman4 @LeXiuning @OncoAlert

2

24

58

17

15.0K

Timothée Olivier, MD Retweeted

A

Ash Paul@pash22 · Jul 16

Oncology “Me-Too”Drugs Compared With Original Drugs in Randomized Clinical Trials acrobat.adobe.com/id/urn:aaid:sc… via @Timothee_MD et al Shocking findings @Maherjane @DrMarkLythgoe @NICEComms @CDA_AMC @iqwig @MHRAgovuk

3

5

13

1

2.0K

Timothée Olivier, MD Retweeted

G

Gordon H. Guyatt@GuyattGH · Jul 14

Advocates suggest administrative real-world data can substitute for #RCTs and offer propensity matching to reduce bias. But results often fail to correspond: #BMJ study showed direction of effect differed in 31% & CI failed to include #RCT estimate in 56% pubmed.ncbi.nlm.nih.gov/26858277/

5

47

113

33

11.0K

T

Timothée Olivier, MD@Timothee_MD · Jul 9

Nice read!

SSaroj Niraula@sarojniraula · Jul 2

Just published: Is iDFS a strong surrogate for OS in #bcsm? My @JCO_ASCO LTE challenges the claim: R² = 0.46 means 54% of OS variance remains unexplained, yet iDFS continues to drive decisions! Oncology needs stronger evidence standards Here: ascopubs.org/doi/10.1200/JC…

0

1

4

0

929

Timothée Olivier, MD Retweeted

S

Saroj Niraula@sarojniraula · Jul 2

Just published: Is iDFS a strong surrogate for OS in #bcsm? My @JCO_ASCO LTE challenges the claim: R² = 0.46 means 54% of OS variance remains unexplained, yet iDFS continues to drive decisions! Oncology needs stronger evidence standards Here: ascopubs.org/doi/10.1200/JC…

0

6

21

7

3.0K

Timothée Olivier, MD Retweeted

O

OncoDaily@oncodaily · Jul 8

We would like to inform you that your post has been published on OncoDaily. Thank you for sharing. oncodaily.com/blog/alfredo-a…

0

1

2

0

283

Timothée Olivier, MD Retweeted

A

Alfredo Addeo MD@Alfdoc2 · Jul 8

Today’s Tuesday scientific colloquium at @hug_ge featured a timely and thought-provoking presentation by @Timothee_MD, on the role of Real-World Data and Real-World Evidence in oncology. How do we bridge the gap between clinical trials and everyday practice? What are the…

1

2

10

0

863

T

Timothée Olivier, MD@Timothee_MD · Jul 6

Updated online applications: 22 @US_FDA approvals in the neoadjuvant and/or adjuvant settings between 2018 and 2025 Number needed to treat? survival benefit? how to interpret survival in the context of post-recurrence care? and more! - registration trials with key data here…

Timothee_MD's tweet image. Updated online applications:
22 @US_FDA approvals in the neoadjuvant and/or adjuvant settings between 2018 and 2025

Number needed to treat? survival benefit? how to interpret survival in the context of post-recurrence care? and more!

- registration trials with key data here…

3

8

21

18

4.0K